JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Strona główna・Stock List・Puma Biotechnology Inc

Puma Biotechnology Inc

Closed

SectorHealthcare

7.44 -0.67

Buy Sell

Overview

Share price change

24h

Current

Min

7.44

Max

7.5

Key metrics
By Trading Economics
Income	3M 12M
Sales	21M 76M
P/E Sector Avg	12.312 67.147
Profit margin	15.633
Employees	179
EBITDA	13M 27M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	-33.24% downside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	24M 382M
Previous open	8.11
Previous close	7.44

News Sentiment

By Acuity

50%

160 / 347 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

3.07 / 3.075 Support & Resistance

Puma Biotechnology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 maj 2026, 21:36 UTC

Acquisitions, Mergers, Takeovers

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1 maj 2026, 20:40 UTC

Acquisitions, Mergers, Takeovers

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1 maj 2026, 18:37 UTC

Major Market Movers

Senseonic Shares Slide on Underwritten Offering Price

1 maj 2026, 16:46 UTC

Major Market Movers

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2 maj 2026, 19:57 UTC

Acquisitions, Mergers, Takeovers

Berkshire CEO Greg Abel Takes the Stage, Making a Case for the Post-Buffett Era -- 3rd Update

2 maj 2026, 15:24 UTC

Earnings

Berkshire CEO Greg Abel Takes the Stage, Talks Through Quarterly Results -- Update

2 maj 2026, 12:46 UTC

Earnings

Acquisitions, Mergers, Takeovers

Berkshire Profits More Than Double on Gains in Insurance, Railroad, Energy Businesses -- WSJ

2 maj 2026, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

1 maj 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

1 maj 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1 maj 2026, 20:42 UTC

Earnings

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1 maj 2026, 19:33 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 maj 2026, 19:33 UTC

Market Talk

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1 maj 2026, 19:18 UTC

Market Talk

Major News Events

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1 maj 2026, 19:13 UTC

Market Talk

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1 maj 2026, 18:36 UTC

Earnings

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1 maj 2026, 18:35 UTC

Earnings

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1 maj 2026, 18:28 UTC

Earnings

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1 maj 2026, 18:27 UTC

Market Talk

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1 maj 2026, 18:14 UTC

Acquisitions, Mergers, Takeovers

Barclays Completes Acquisition of Best Egg

1 maj 2026, 18:04 UTC

Earnings

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1 maj 2026, 17:43 UTC

Market Talk

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1 maj 2026, 17:37 UTC

Market Talk

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1 maj 2026, 17:30 UTC

Market Talk

Earnings

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1 maj 2026, 17:28 UTC

Market Talk

Earnings

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1 maj 2026, 17:21 UTC

Market Talk

Earnings

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1 maj 2026, 17:19 UTC

Market Talk

Major News Events

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1 maj 2026, 16:38 UTC

Market Talk

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1 maj 2026, 16:23 UTC

Acquisitions, Mergers, Takeovers

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1 maj 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Peer Comparison

Price change

Puma Biotechnology Inc Forecast

Price Target

By TipRanks

-33.24% downside

12 Months Forecast

Average 5 USD -33.24%

High 5 USD

Low 5 USD

Based on 1 Wall Street analysts offering 12 month price targets forPuma Biotechnology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Puma Biotechnology Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.07 / 3.075Support & Resistance

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

160 / 347 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.